BURLINGAME, Calif., Sept. 1, /PRNewswire/ -- ChemBridge Corporation, a leading discovery chemistry company offering an extensive portfolio of discovery chemistry products and contract research services, has now made ten of their most popular screening libraries available to researchers via the Collaborative Drug Discovery (CDD) Public Access database. Now for the first time, researchers can access ChemBridge Libraries alongside a growing body of public data from leading vendors, researchers, scientific literature, and patent resources. CDD subscribers can access the data directly from their private groups, mining the libraries using their own private data to more effectively identify compounds of interest within the ChemBridge datasets, increasing the efficiency of identifying drug candidates. "The CDD database is an effective platform for biological and chemical data storage and mining, and knowing that a number of our client companies and research organizations are actively using the CDD database, we wanted to ensure that our clients could easily integrate ChemBridge screening library data into their workflow within the CDD database," said Duncan Beniston, Executive Director Sales & Marketing, ChemBridge.
With the CDD database previously consisting of well over a million compounds, ChemBridge's libraries join an impressive list of co-contributors. With the ongoing help of academic, non-profit, and industry contributors, CDD is continuously expanding the public database with both chemical and biological data. Collectively, these data sets and the software are being accessed by thousands of cutting edge researchers around the world. Anyone can register for free read-only access to these new and all public data sets on CDD's website (www.collaborativedrug.com/register), read-and-write access (including the ability to archive, mine, and collaborate around private data and to import and export both private and public data) can be accessed following a free trial with full commercial access (contact: firstname.lastname@example.org). The compounds are available for testing hypotheses from ChemBridge (www.chembridge.com), additional molecules not in the public site can be ordered and the corresponding structures can also be archived in private sites and linked to biological activity data.
About ChemBridge Corporation
ChemBridge Corporation, www.chembridge.com, is a leading global discovery chemistry company providing custom chemistry services, small molecule screening compound libraries and specialty building blocks for organic synthesis. ChemBridge is a San Diego based company with an impeccable 15 year track record of quality and deliverability and operates a state-of-the-art offshore discovery chemistry research site in Moscow, Russia. ChemBridge's CRO business includes multi-year strategic alliances with major pharmaceutical companies as well as mid-size pharmaceutical and biotech companies. Over 500 pharmaceutical and biotech companies and universities worldwide have also taken advantage of ChemBridge's portfolio of products, including its library of 10,000 specialty building blocks and 800,000 drug-like and lead-like small molecule screening compounds.
SOURCE Collaborative Drug Discovery
CONTACT: Barry Bunin, Ph.D., President & CEO, of Collaborative Drug
Discovery (CDD), email@example.com; or Duncan Beniston, Executive
Director, Sales & Marketing, of ChemBridge Corporation, +1-858-451-7400,
Web site: http://www.chembridge.com/